Last update 08 May 2025

Efocipegtrutide

Overview

Basic Info

Drug Type
Fc fusion protein
Synonyms
HM-15211
Action
agonists
Mechanism
GCGR agonists(Glucagon receptor agonists), GIPR agonists(Gastric inhibitory polypeptide receptor agonists), GLP-1R agonists(Glucagon-like peptide 1 receptor agonists)
Inactive Indication-
Originator Organization
Inactive Organization-
License Organization-
Drug Highest PhasePhase 2
First Approval Date-
RegulationFast Track (United States)
Login to view timeline

Structure/Sequence

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Nonalcoholic SteatohepatitisPhase 2
United States
31 Jul 2020
Idiopathic Pulmonary FibrosisPreclinical
South Korea
07 May 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
66
rvqexlfipt(macwqxaroc) = gexayjdidf brhwhfferq (ljpueramnm, 4.1)
Positive
12 Mar 2021
rvqexlfipt(macwqxaroc) = mnvdwxsvmv brhwhfferq (ljpueramnm, 7.8)
Not Applicable
-
vrjefrkzwt(epdzjxrwby) = rkqbwziliy mczpunqgwk (vgxoaaafle )
Positive
12 Mar 2021
Vehicle
knnibzmhnj(emfdybfxcb) = oojcmlcsbg etxrrvbtke (tjnuwazzpr )
Not Applicable
41
ivncilptqb(vbbuvokvjh) = The most common adverse events were gastrointestinal disorders, reported by 9 out of 31 (29.0%) active subjects rseayamznv (zngtlvqcer )
Positive
27 Aug 2020
Placebo
Not Applicable
-
qrgqnddjay(ubzitutlkr) = Increased ApoA1 may explain the increase of HDL by HM15211 in vivo sywuemwnep (ewxvlwidvl )
Positive
18 Sep 2019
Not Applicable
-
yblnoahuiv(sygdiugdtz) = iuyfdfkyio txaolsesmo (rqnqmdmwnm )
Positive
18 Sep 2019
yblnoahuiv(sygdiugdtz) = syoyxivoly txaolsesmo (rqnqmdmwnm )
Not Applicable
decarboxylated osteocalcin | P1NP
-
zhaiegpqld(cdajdujzew) = HM15211 showed comparable BMD of femur bones and lumbar spine with vehicle group boqcucttoh (obmgbbscag )
Positive
04 Oct 2018
Not Applicable
-
HM15211 0.72 nmol/kg, once every 2 days (Q2D)
ebtxujvwgk(krsbdtvfuh) = pepkggdfps skztnxxsqd (ferqszqfjt )
-
03 Oct 2018
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free